VVUS Related FDA
-
VIVUS, Inc. (VVUS) to Make Several Scientific Presentations in May
-
VIVUS, Inc. (VVUS) Pops as Larger Qsymia Retail Presence Expected Soon
-
Arena (ARNA) Clears Final BELVIQ Marketing Hurdle; Could Make U.S. Debut in June
-
VIVUS, Inc. (VVUS) Ticks Higher as Arena (ARNA) Pulls BELVIQ MAA in Europe
-
VIVUS, Inc. (VVUS) Avanafil Receives Positive CHMP Opinion
-
VIVUS (VVUS) Qsymia Growth Seen at 55% in Q1 from Q4
-
VIVUS (VVUS) March Qsymia Shipments Rose 29%
-
VIVUS, Inc. (VVUS) Qsymia Receives FDA Approval for REMS Modification
-
VIVUS, Inc. (VVUS) Positive; Shorts Cover Into REMS Modification for Qsymia
-
VIVUS (VVUS) Qsymia Prescriptions Fall for Second Week; Promotion Still Ongoing
-
VIVUS (VVUS) Enters $110M non-Equity Financing Agreement; Will Draw $50M Initially
-
Arena (ARNA), VIVUS (VVUS) Face Uphill Obesity Battle as Costs Play Key Role
-
VIVUS, Inc. (VVUS) Debuts New Save Now! Program for Qsymia
-
Needham Sees Strong Start for Arena's (ARNA) Belviq in U.S.; European Approval Unlikely
-
VIVUS (VVUS) Cuts Qsymia Price by About 70%; Arena (ARNA) on Watch
-
UPDATE: VIVUS, Inc. (VVUS) Posts Q4 Loss of 56c/Share
-
Arena (ARNA) Will Need Lower Co-Payments, Broader Coverage for Belviq Success (VVUS)
-
EMA CHMP Declines VIVUS (VVUS) MAA for Qsiva
-
Risks vs. Benefits of Bariatric Surgery Might Put Obesity Pills in Lime Light (ARNA) (VVUS) (OREX)
-
VIVUS, Inc. (VVUS) Qsymia Prescriptions Show Gains During Slow Holiday Week (ARNA) (OREX)
-
VIVUS (VVUS) Peers Tick Higher Amid Positive Qsymia Data (ARNA) (OREX)
-
VIVUS (VVUS) Reports Publication of Signifianct Data from Recent Qsymia Study
-
Obesity Pill Makers in Focus as EMA CHMP Denies Belviq MAA (ARNA) (VVUS) (OREX)
-
VIVUS (VVUS) Qsymia Prescriptions Jump 140%+ After Free Trial Program Starts
-
VIVUS (VVUS) Qsymia Sales Lag Investor Sentiment in Nov.; Many Expect Better FY13
-
Express Scripts (ESRX) Deal is Huge Win for VIVUS (VVUS); Qsymia Reimbursement Will Improve
-
JPMorgan Confident Orexigen's (OREX) Will Receive FDA Approval; Comments on Meeting
-
Arena (ARNA), Orexigen (OREX) on Watch as Major PBM Adds Qsymia to Formularies List (VVUS)
-
VIVUS (VVUS) Says Qsymia Now Covered by Express Scripts' (ESRX)
-
Orexigen (OREX) Slumps as Many Expected 'Better News' for Contrave
-
Vivus (VVUS) Surges as Qsymia Prescriptions Rise 46%
-
VIVUS (VVUS) Qsymia Prescriptions Pop Following Thanksgiving Glut (ARNA) (OREX)
-
VIVUS, Inc. (VVUS) Begins Qsymia Free Trial Offer Program (CVS) (WAG)
-
Vivus (VVUS) Announces Significant Data from Obstructive Sleep Apnea Trial
-
VIVUS, Inc. (VVUS) Posts Wider than Expected Q3 Loss of 40c/Share
-
VIVUS (VVUS) Qsymia Prescriptions Now Said to Be Up 25% in Week 6, In-Line with Views
-
VIVUS (VVUS) Lower; Data Shows Unexpected Drop in Qsymia Prescriptions for Week 6 - BI
-
VIVUS (VVUS) Qsymia Prescriptions Remain High Amid Birth Defect Warning; Positive for Arena (ARNA)
-
VIVUS (VVUS) Qsymia Prescriptions Keep Chugging, Gain 27%+ Last Week
-
Orexigen (OREX) Pops Higher as Contrave May Get Speedier Approval (VVUS) (ARNA)
-
Wells Outlines Paths for VIVUS (VVUS) Following CHMP Denial of Qsiva Marketing App
-
VIVUS (VVUS) Formally Denied MAA for Qsiva by CHMP; Cites Concern Over Cadio, Nervous System Effects
-
Arena (ARNA) Runs Higher as VIVUS (VVUS) Seeks Broader Obesity Pill Distribution
-
VIVUS (VVUS) Submits Amdendment to REMS for Qsymia to Expand Distribution
-
Arena (ARNA) Partner Eisai May Also Have Promising Weight-Loss Pill in the Works
-
FDA Might Allow for Faster Approval of Obesity Drugs (VVUS) (ARNA) (OREX)
-
VIVUS (VVUS) Higher as Qsymia Prescriptions Show Confident Growth
-
Arena (ARNA) Higher as Large PBM Joins Obesity Pill Distribution Network (VVUS)
-
Express Scripts (ESRX) Becomes Part of Qsymia Home Delivery Network (VVUS)
-
Vivus (VVUS) to Make Several Qsymia Presentations at 48th EASD
Back to VVUS Stock Lookup
